About us

We are a physics driven drug discovery company. Using advanced simulation software and AI-enhanced medicinal chemistry, we develop novel drug candidates and innovative mode of action against challenging targets. We design our drug candidates atom by atom to optimize their efficiency and their specificity with a favorable safety profile at unprecedented speed.

We build upon more than 30 years of R&D awarded by the most prestigious prizes such as 2 ERC grants and the ATOS Fourier prize. We spun-off from leading research institutions in France and in the USA : CNAM, CNRS, University of Texas at Austin, Sorbonne University and Washington University, in Saint Louis and we are based in Paris, at the very heart of “Le quartier Latin” and in Boston.

We are supported by three major deeptech investment funds Quantonation, Xange and Omnes Capital. In less than 18 months, we have built an impressive track record of awards such as the EIC accelerator thanks to our team and the technology.

We are embarking the most brilliant minds in theory, methods, software and drug design from both sides of the Atlantic to deliver on our mission and improve people’s lives.

0
People based in Paris & Boston
0
Active drug discovery programs
0
Proprietary supercomputer (25 pflops) & cloud computing extension
0
1 proprietary drug discovery platform, ATLAS
M$0
raised

The Founders

Pr Jay Ponder
Pr Jay PonderWashington University in St. Louis, Chemistry and Biochemistry & Molecular Biophysics
Read biography
Pr Pengyu Ren
Pr Pengyu Ren University of Texas at Austin, Biomedical Engineering
Read biography
Pr J.-P. Piquemal, CSO
Pr J.-P. Piquemal, CSOSorbonne Université, Laboratoire de Chimie Théorique
Read biography
Dr Louis Lagardère
Dr Louis LagardèreSorbonne Université, Laboratoire de Chimie Théorique
Read biography
Pr Matthieu Montes
Pr Matthieu MontesCNAM, Laboratoire de génomique, bioinformatique et chimie moléculaire
Read biography

The Team

We have assembled an international team with significant scientific and industrial expertise. Our complementary expertise covers all the disciplines involved in drug discovery and ranges from quantum chemistry and physics, HPC, computer-aided drug design, medicinal chemistry, artificial intelligence and structural biology.

Elettra Baldacci
Elettra BaldacciOffice Manager
Read biography
Dina El Ahdab, PhD
Dina El Ahdab, PhDResearch Scientist
Read biography
Léa El Khoury, PhD
Léa El Khoury, PhDTeam Leader in Molecular Modeling
Read biography
Jérome Foret, PhD
Jérome Foret, PhDChief Platform Officer
Read biography
Nicolai Gouraud
Nicolai GouraudJunior research scientist quantum chemistry and physics
Read biography
Florent Hédin, PhD
Florent Hédin, PhDSenior HPC Engineer
Read biography
Chris Ho, MD, PhD
Chris Ho, MD, PhDSenior Research Scientist
Francis Jing, PhD
Francis Jing, PhDResearch Scientist
Read biography
Daniele Loco, PhD
Daniele Loco, PhDResearch Scientist in quantum chemistry and physics
Read biography
Robert Marino, PhD
Robert Marino, PhDCEO
Read biography
Yassine Naimi
Yassine NaimiBioinformatic Engineer
Read biography
Manon Réau, PhD
Manon Réau, PhDResearch Scientist
Read biography
Boris Sattarov
Boris SattarovTeam lead : AI assisted de novo design
Read biography

Our Values

Science Excellency & Quality

First

Multi-disciplinary

Second

Trust & Integrity

Third

Curiosity

also

Loyality & Managed Ego

last but not least

Board members representing the investors

Fabien Collangettes
Fabien Collangettes Investment Director, Omnes Capital
Christophe Jurczak
Christophe Jurczak Managing Partner, Quantonation
Guilhem de Vregille
Guilhem de VregillePartner, Xange

They support us